Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Petra, Flygare"'
Autor:
Sampsa Kinos, Helga Hagman, Päivi Halonen, Leena-Maija Soveri, Mary O'Reilly, Per Pfeiffer, Jan-Erik Frödin, Halfdan Sorbye, Eetu Heervä, Gabor Liposits, Raija Kallio, Annika Ålgars, Raija Ristamäki, Tapio Salminen, Maarit Bärlund, Carl-Henrik Shah, Ray McDermott, Rebecka Röckert, Petra Flygare, Johannes Kwakman, Arco Teske, Cornelis Punt, Bengt Glimelius, Pia Österlund
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background and purpose: The CardioSwitch-study demonstrated that patients with solid tumors who develop cardiotoxicity on capecitabine or 5-fluorouracil (5-FU) treatment can be safely switched to S-1, an alternative fluoropyrimidine (FP). In light of
Externí odkaz:
https://doaj.org/article/340dd2f28c5441ddaf0adaf8e0022afa
Autor:
Ylva Naeser, Hildur Helgadottir, Yvonne Brandberg, Johan Hansson, Roger Olofsson Bagge, Nils O. Elander, Christian Ingvar, Karolin Isaksson, Petra Flygare, Cecilia Nilsson, Frida Jakobsson, Olga del Val Munoz, Antonis Valachis, Malin Jansson, Charlotte Sparring, Lars Ohlsson, Ulf Dyrke, Dimitrios Papantoniou, Anders Sundin, Gustav J. Ullenhag
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background The incidence of cutaneous malignant melanoma (CMM) is increasing worldwide. In Sweden, over 4600 cases were diagnosed in 2018. The prognosis after radical surgery varies considerably with tumor stage. In recent years, new treatme
Externí odkaz:
https://doaj.org/article/0c95732cbbdb48428677ce4543c2d318
Autor:
Frida Jakobsson, Dimitrios Papantoniou, Lars Ohlsson, Johan Hansson, Cecilia Nilsson, Petra Flygare, Charlotte Sparring, Karolin Isaksson, Hildur Helgadottir, Nils O. Elander, Malin Jansson, Ylva Naeser, Antonis Valachis, Yvonne Brandberg, Gustav J. Ullenhag, Roger Olofsson Bagge, Anders Sundin, Christian Ingvar, Olga del Val Munoz, Ulf Dyrke
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Cancer
BMC Cancer
Background The incidence of cutaneous malignant melanoma (CMM) is increasing worldwide. In Sweden, over 4600 cases were diagnosed in 2018. The prognosis after radical surgery varies considerably with tumor stage. In recent years, new treatment option
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8fdf1f19973c77fea680dc117ea756a
https://doaj.org/article/0c95732cbbdb48428677ce4543c2d318
https://doaj.org/article/0c95732cbbdb48428677ce4543c2d318
Autor:
Ullenhag, Ylva Naeser, Hildur Helgadottir, Johan Hansson, Christian Ingvar, Nils O. Elander, Petra Flygare, Cecilia Nilsson, Frida Jakobsson, Antonios Valachis, Dimitrios Papantoniou, Agneta Nordin Danfors, Hemming Johansson, Anders Sundin, Yvonne Brandberg, Gustav J.
Publikováno v:
Cancers; Volume 14; Issue 4; Pages: 1040
The benefit of imaging in the follow-up setting for high-risk melanoma patients is uncertain, and even less is known about the impact of intensive follow-up on the patient´s quality of life. In 2017, a Swedish prospective randomized multicenter stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::96cafe5cbc75239f5b058504cce4a818
Autor:
Ylva, Naeser, Hildur, Helgadottir, Johan, Hansson, Christian, Ingvar, Nils O, Elander, Petra, Flygare, Cecilia, Nilsson, Frida, Jakobsson, Antonios, Valachis, Dimitrios, Papantoniou, Agneta, Nordin Danfors, Hemming, Johansson, Anders, Sundin, Yvonne, Brandberg, Gustav J, Ullenhag
Publikováno v:
Cancers. 14(4)
The benefit of imaging in the follow-up setting for high-risk melanoma patients is uncertain, and even less is known about the impact of intensive follow-up on the patient´s quality of life. In 2017, a Swedish prospective randomized multicenter stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d509aa5bf84655727a668dbda7186980
https://pubmed.ncbi.nlm.nih.gov/35205786
https://pubmed.ncbi.nlm.nih.gov/35205786
Autor:
Helga Hagman, Raija Ristamäki, Gabor Liposits, R. Röckert, Eetu Heervä, Per Pfeiffer, S. Kinos, R. Kwakman, Raija Kallio, Raymond S. McDermott, Carl Henrik Shah, A. Teske, E. van Werkhoven, Leena-Maija Soveri, Annika Ålgars, Halfdan Sorbye, C.J.A. Punt, Petra Flygare, Pia Österlund, T. Salminen, P. Halonen, Bengt Glimelius
Publikováno v:
Annals of Oncology. 31:239
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::55d26aac3676b2a45ba301d385b460de
https://doi.org/10.1016/j.annonc.2020.04.072
https://doi.org/10.1016/j.annonc.2020.04.072
Autor:
Gabor Liposits, Raymond S. McDermott, Raija Kallio, Halfdan Sorbye, Bengt Glimelius, Johannes J.M. Kwakman, Annika Ålgars, Erik van Werkhoven, T. Salminen, Rebecka Röckert, Petra Flygare, Cornelis J. A. Punt, Helga Hagman, Eetu Heervä, Per Pfeiffer, P. Halonen, L. M. Soveri, Sampsa Kinos, Carl-Henrik Shah, Pia Österlund
Publikováno v:
Österlund, P, Kinos, S, Halonen, P, Soveri, L-M, Kwakman, J J, Salminen, T, McDermott, R S, Pfeiffer, P, Heervä, E, Istvan Liposits, G, Röckert, R, Ålgars, A, Kallio, R S, Sorbye, H, Flygare, P, Hagman, H, Shah, C-H, Werkhoven, E D V, Glimelius, B, Punt, C J A & Cardioswitch Group 2020, ' Feasibility of switching to S-1 after other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors. ', Journal of Clinical Oncology, vol. 38, no. 15 Suppl., pp. 7037 . https://doi.org/10.1200/jco.2020.38.15_suppl.7037
7037 Background: Fluoropyrimidines (FP) are the cornerstone of chemotherapy in many solid tumors and linked to cardiotoxicity (CarTx) in about 5% (Polk, Cancer Treat Rev 2013), often leading to FP discontinuation. CarTx may be less common with S-1 an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a2687921bc5fce0128f6fa74dcbc3bc
https://doi.org/10.1200/jco.2020.38.15_suppl.7037
https://doi.org/10.1200/jco.2020.38.15_suppl.7037
Autor:
Andrzej Piwowar, Fransje Aa Valster, Jeffrey P.B.M. Braak, Marije Ie Appels, Frits van Coevorden, Niels H Nielsen, Johanna E.A. Portielje, Jeroen Buijsen, Petra Flygare, Marije Slingerland, Nicole C.T. van Grieken, Jetske M. Meerum Terwogt, Maartje Los, Mattias Elmlund, Henk Boot, Rob L. H. Jansen, Johanna W. van Sandick, A. Haringhuizen, Johannes J. Bonenkamp, Harm van Tinteren, Edwin P.M. Jansen, Henk H. Hartgrink, Jaap De Boer, Anouk K. Trip, Ge Jpm Jonkers, Marie Louise Jespersen, Cecillia Lagerbäck, Per Edlund, Marco B Polée, Mats Perman, J (Hans)-Martin Mb Otten, Marjan A Van Dijk, Danny Houtsma, A (Bert) Jan Ten Tije, Arnold Baars, Olaf Jl Loosveld, Maud M. Geenen, Maarten C.C.M. Hulshof, Gerrit-Jan Veldhuis, Erik W Muller, Geert-Jan Creemers, Annelie Je Vulink, Quirijn A. J. Eijsbouts, Annerie Slot, Diane Grootenboers, Hein Putter, Ellen M Hendriksen, Maurice J.C. van der Sangen, Fabiënne A. R. M. Warmerdam, Tom Rozema, HA A. Maurits Swellengrebel, Henk K Van Halteren, Ate van der Gaast, Marcel Verheij, Richard Van Hilligersberg, Helene Hörberg, Pehr Lind, Annemieke Cats, Cornelis J.H. van de Velde, Jitty M Smit, Alex L. T. Imholz, Donald L. van der Peet, Aart Van Bochove, Henk M.W. Verheul, Adelheid Me Van der Torren-Conze, Frans L. G. Erdkamp, Dick Johan van Spronsen, Mark I. van Berge Henegouwen, Ernst Jan Spillenaar Bilgen, Johanna Mgh Van Riel, Marien O Den Boer, Hanneke W. M. van Laarhoven, Marjolein Em Rentinck, Ron C Rietbroek, Bengt Johansson, David Borg, Anders Johnsson, Aart Beeker, Reinoud J. B. Blaisse, Miriam Koopman, Daan Ten Bokkel Huinink, Karen J. Neelis, Elma Meershoek-Klein Kranenbarg, Djamila Boerma, Heleen M. Ceha, Bea C Tanis, Marie-Cecile Jc Legdeur, O Aart Van Dobbenburgh, Steven Vanhoutvin, Sjoerd Hovenga, Karolina Sikorska, Pètra M Braam, H Pieter van den Berg, Huub van der Mijle, Marianne Nordsmark, Bengt Glimelius
Publikováno v:
lancet oncology, 19(5), 616-628. Lancet Publishing Group
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet Oncology, 19, 5, pp. 616-628
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS)-an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet oncology, 19(5), 616-628. Elsevier Science
Lancet Oncology, 19, 616-628
The Lancet Oncology, 19(5), 616-628
The Lancet Oncology, 19(5), 616-628. Lancet Publishing Group
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet Oncology, 19, 5, pp. 616-628
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS)-an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet oncology, 19(5), 616-628. Elsevier Science
Lancet Oncology, 19, 616-628
The Lancet Oncology, 19(5), 616-628
The Lancet Oncology, 19(5), 616-628. Lancet Publishing Group
Item does not contain fulltext BACKGROUND: Both perioperative chemotherapy and postoperative chemoradiotherapy improve survival in patients with resectable gastric cancer from Europe and North America. To our knowledge, these treatment strategies hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b21019f3b155741c37a17771cdb957cb
https://pure.amc.nl/en/publications/chemotherapy-versus-chemoradiotherapy-after-surgery-and-preoperative-chemotherapy-for-resectable-gastric-cancer-critics-an-international-openlabel-randomised-phase-3-trial(8c4f223a-519d-480e-ad66-3d7eaea704e6).html
https://pure.amc.nl/en/publications/chemotherapy-versus-chemoradiotherapy-after-surgery-and-preoperative-chemotherapy-for-resectable-gastric-cancer-critics-an-international-openlabel-randomised-phase-3-trial(8c4f223a-519d-480e-ad66-3d7eaea704e6).html
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 38:677-683
Purpose: The goal of this study was to investigate the clinical utility of pretreatment measurements of tumor cell kineticsto predict the outcome of patients with squamous cell carcinoma of the head and neck receiving conventional radiotherapy. Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ae7deab12149cea5532b53babac7108
https://doi.org/10.1016/s0360-3016(97)00066-7
https://doi.org/10.1016/s0360-3016(97)00066-7
Autor:
Åke Berglund, Ingegerd Karlberg, Petra Flygare, Anders Johnsson, Michael Gubanski, Eva Fernebro, Bengt Glimelius, Lianna Kadar, Pehr Lind
Publikováno v:
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 13(3)
Background. The optimal chemotherapy in patients with advanced gastric carcinoma (GC) is yet to be determined. We compared sequential administration of docetaxel and irinotecan, both in combination with infused 5-fluorouracil/leucovorin (5-Fu/Lv), an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db3eea34da934779a93936027cec05ac
https://pubmed.ncbi.nlm.nih.gov/20820984
https://pubmed.ncbi.nlm.nih.gov/20820984